Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...
Life-saving antibiotics that could treat severe infections in babies and children aren't accessible due to a lack of data ...
Company to Participate in BIO Partnering Summit and Present Phase 1 Ketamir-2 Data at American Association for Cancer ...
Rocatinlimab, targeting the OX40 pathway, shows significant efficacy in moderate to severe atopic dermatitis, marking a new therapeutic class in disease management. Long-term melanoma data reveal ...
PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...
Licensed scientific and clinical intelligence integrated into the 3RnD platform to support AI-Driven Discovery and ...
PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the ...
Efficiency and accelerating clinical trial timelines have emerged as key themes at this year’s annual SCOPE Summit in Orlando, FL. The opening keynote panel of the event moderated by Jeremy Goldberg, ...
In a new draft guidance issued on January 14, 2026, the FDA discussed the use of a modern statistical methodology in clinical trials designed to ...
1) the active drug substance Axitinib, which used to belong to Pfizer, is an FDA-approved, oral, potent VEGFR inhibitor. So ...
U.S. clinical trials for ALS do not include enough non-white patients and women to reflect the disease's real-world prevalence, per a study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results